Pfizer Inc. $PFE Shares Bought by SSA Swiss Advisors AG

SSA Swiss Advisors AG grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 13.4% in the second quarter, according to its most recent filing with the SEC. The firm owned 126,369 shares of the biopharmaceutical company’s stock after acquiring an additional 14,900 shares during the quarter. SSA Swiss Advisors AG’s holdings in Pfizer were worth $3,197,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Capital Advisory Group Advisory Services LLC boosted its position in shares of Pfizer by 2.9% in the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock worth $328,000 after purchasing an additional 388 shares during the last quarter. Citizens National Bank Trust Department raised its stake in Pfizer by 0.9% during the 2nd quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock worth $1,118,000 after buying an additional 395 shares during the period. Trust Co of the South raised its stake in Pfizer by 1.5% during the 2nd quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock worth $712,000 after buying an additional 441 shares during the period. Charter Oak Capital Management LLC raised its stake in Pfizer by 4.3% during the 2nd quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company’s stock worth $258,000 after buying an additional 444 shares during the period. Finally, Ballentine Partners LLC raised its stake in Pfizer by 0.5% during the 2nd quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company’s stock worth $2,260,000 after buying an additional 458 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE:PFE opened at $24.79 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock’s 50-day simple moving average is $24.87 and its 200 day simple moving average is $24.17. The company has a market cap of $140.92 billion, a P/E ratio of 13.18, a P/E/G ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.17.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Analyst Ratings Changes

Several brokerages recently commented on PFE. Morgan Stanley dropped their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. UBS Group reissued a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Citigroup lifted their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Finally, Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer has a consensus rating of “Hold” and an average target price of $28.13.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.